Cholangitis Clinical Trials

60 recruitingLast updated: July 25, 2026

There are 60 actively recruiting cholangitis clinical trials across 44 countries. Studies span Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1, Phase 4. Top locations include Seattle, Washington, United States, Xi'an, Shaanxi, China, London, United Kingdom. Updated daily from ClinicalTrials.gov.


Cholangitis Trials at a Glance

60 actively recruiting trials for cholangitis are listed on ClinicalTrialsFinder across 6 cities in 44 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Seattle, Xi'an, and London. Lead sponsors running cholangitis studies include Xijing Hospital of Digestive Diseases, Ipsen, and Children's Hospital Medical Center, Cincinnati.

Browse cholangitis trials by phase

Treatments under study

About Cholangitis Clinical Trials

Looking for clinical trials for Cholangitis? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cholangitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cholangitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 60 trials

Recruiting

Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach

Primary Sclerosing Cholangitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)143 enrolled1 locationNCT04685200
Recruiting
Phase 2

Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

Liver Transplant; ComplicationsPrimary Sclerosing CholangitisPSC+1 more
Mayo Clinic80 enrolled1 locationNCT06905054
Recruiting
Phase 3

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Primary Biliary Cholangitis
Gilead Sciences318 enrolled205 locationsNCT06051617
Recruiting

Primary Sclerosing Cholangitis in Children

Liver DiseasesPrimary Sclerosing CholangitisCholangitis, Sclerosing
Arbor Research Collaborative for Health1,000 enrolled12 locationsNCT04181138
Recruiting
Phase 3

A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

Primary Biliary Cholangitis
Cascade Pharmaceuticals, Inc135 enrolled42 locationsNCT07282353
Recruiting
Phase 3

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis
Ipsen350 enrolled4 locationsNCT07387549
Recruiting
Phase 3

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis (PBC)
Ipsen276 enrolled186 locationsNCT06016842
Recruiting

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

Primary Biliary Cholangitis
Ipsen424 enrolled68 locationsNCT06447168
Recruiting
Phase 1Phase 2

A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

Primary Biliary Cholangitis (PBC)
Umecrine Cognition AB84 enrolled40 locationsNCT07304843
Recruiting

Composite Index for Outcome Burden in Acute Cholangitis

Acute CholangitisBiliary Drainage
Asian Institute of Gastroenterology, India514 enrolled1 locationNCT07667166
Recruiting
Not Applicable

Sedation Methods in Percutaneous Transhepatic Biliary Drainage: Procedure Quality and Recovery

MalignancyFragilityCholangitis+1 more
Ankara City Hospital Bilkent98 enrolled1 locationNCT07640243
Recruiting
Not Applicable

Biodegradable Stents in Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis (PSC)
King's College Hospital NHS Trust20 enrolled1 locationNCT07607353
Recruiting
Early Phase 1

Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC

Primary Sclerosing Cholangitis
University of Minnesota28 enrolled1 locationNCT06197308
Recruiting

Austrian PBC Registry

Liver CirrhosisPrimary Biliary CholangitisPortal Hypertension
Medical University of Vienna500 enrolled11 locationsNCT07598669
Recruiting
Phase 2

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Primary Biliary CholangitisPBC
Mirum Pharmaceuticals, Inc.260 enrolled130 locationsNCT05050136
Recruiting
Not Applicable

Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy

Biliary AtresiaCholangitisAnti-Bacterial Agents
Children's Hospital of Fudan University356 enrolled1 locationNCT05925309
Recruiting
Phase 2

FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis

Inflammatory Bowel DiseasesPrimary Sclerosing Cholangitis
University of Birmingham58 enrolled5 locationsNCT06286709
Recruiting

Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome

Non-Alcoholic Fatty Liver DiseaseAutoimmune HepatitisPrimary Sclerosing Cholangitis+2 more
Chungnam National University Hospital3,000 enrolled1 locationNCT06519162
Recruiting
Phase 1

A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

Healthy VolunteersPrimary Sclerosing Cholangitis
Takeda134 enrolled1 locationNCT07229911
Recruiting

Biochemical Response and Clinical Outcomes in Patients With PBC

Primary Biliary CholangitisPrimary Biliary Cholangitis (PBC)
RenJi Hospital3,000 enrolled1 locationNCT07449793